
EquitySector - HealthcareVery High Risk
Regular
NAV (30-Apr-26)
Returns (Since Inception)
Fund Size
₹1,056 Cr
Expense Ratio
2.28%
ISIN
INF789F01695
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
28 Jun 1999
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+8.33%
+7.06% (Cat Avg.)
3 Years
+24.95%
+23.61% (Cat Avg.)
5 Years
+14.00%
+14.03% (Cat Avg.)
10 Years
+12.72%
+13.90% (Cat Avg.)
Since Inception
+14.59%
— (Cat Avg.)
| Equity | ₹1,041.49 Cr | 98.67% |
| Others | ₹14.04 Cr | 1.33% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹105.43 Cr | 9.99% |
| Ajanta Pharma Ltd | Equity | ₹67.56 Cr | 6.40% |
| Lupin Ltd | Equity | ₹62.48 Cr | 5.92% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹42.63 Cr | 4.04% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹39.32 Cr | 3.73% |
| Gland Pharma Ltd | Equity | ₹36.51 Cr | 3.46% |
| Dr Reddy's Laboratories Ltd | Equity | ₹36.39 Cr | 3.45% |
| Divi's Laboratories Ltd | Equity | ₹36.12 Cr | 3.42% |
| Alkem Laboratories Ltd | Equity | ₹36.03 Cr | 3.41% |
| Fortis Healthcare Ltd | Equity | ₹31.8 Cr | 3.01% |
| Aurobindo Pharma Ltd | Equity | ₹31.47 Cr | 2.98% |
| Cohance Lifesciences Ltd | Equity | ₹29.14 Cr | 2.76% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹27.77 Cr | 2.63% |
| Ipca Laboratories Ltd | Equity | ₹25.16 Cr | 2.38% |
| Anthem Biosciences Ltd | Equity | ₹24.52 Cr | 2.32% |
| Procter & Gamble Health Ltd | Equity | ₹23.99 Cr | 2.27% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹23.14 Cr | 2.19% |
| Sudeep Pharma Ltd | Equity | ₹22.54 Cr | 2.14% |
| Sai Life Sciences Ltd | Equity | ₹22.32 Cr | 2.11% |
| Caplin Point Laboratories Ltd | Equity | ₹21.82 Cr | 2.07% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹21.74 Cr | 2.06% |
| Global Health Ltd | Equity | ₹20.25 Cr | 1.92% |
| Viyash Scientific Ltd | Equity | ₹20.05 Cr | 1.90% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹19.46 Cr | 1.84% |
| Cipla Ltd | Equity | ₹18.36 Cr | 1.74% |
| Pfizer Ltd | Equity | ₹18.12 Cr | 1.72% |
| Marksans Pharma Ltd | Equity | ₹17.83 Cr | 1.69% |
| Metropolis Healthcare Ltd | Equity | ₹16.79 Cr | 1.59% |
| Rainbow Childrens Medicare Ltd | Equity | ₹16.77 Cr | 1.59% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹14.3 Cr | 1.36% |
| Net Current Assets | Cash | ₹13.95 Cr | 1.32% |
| Dr. Lal PathLabs Ltd | Equity | ₹13.12 Cr | 1.24% |
| Windlas Biotech Ltd | Equity | ₹12.19 Cr | 1.16% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹11.4 Cr | 1.08% |
| Emcure Pharmaceuticals Ltd | Equity | ₹11.05 Cr | 1.05% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹10.39 Cr | 0.98% |
| Aarti Pharmalabs Ltd | Equity | ₹8.88 Cr | 0.84% |
| Jubilant Pharmova Ltd | Equity | ₹7.32 Cr | 0.69% |
| Biocon Ltd | Equity | ₹7.22 Cr | 0.68% |
| Syngene International Ltd | Equity | ₹7.02 Cr | 0.66% |
| Acutaas Chemicals Ltd | Equity | ₹6.4 Cr | 0.61% |
| Laxmi Dental Ltd | Equity | ₹6.37 Cr | 0.60% |
| Alembic Pharmaceuticals Ltd | Equity | ₹5.47 Cr | 0.52% |
| Orchid Pharma Ltd | Equity | ₹4.82 Cr | 0.46% |
| Clearing Corporation Of India Ltd. Std - Margin | Cash - Repurchase Agreement | ₹0.09 Cr | 0.01% |
Large Cap Stocks
24.95%
Mid Cap Stocks
26.68%
Small Cap Stocks
47.04%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹1,035.1 Cr | 98.06% |
| Basic Materials | ₹6.4 Cr | 0.61% |
Standard Deviation
This fund
16.56%
Cat. avg.
16.46%
Lower the better
Sharpe Ratio
This fund
1.05
Cat. avg.
0.96
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.70
Higher the better
Since May 2022
ISIN INF789F01695 | Expense Ratio 2.28% | Exit Load 1.00% | Fund Size ₹1,056 Cr | Age 26 years 10 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹3,25,054 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments